Comparable Safety And Immunogenicity And Sustained Efficacy After Transition To Sb2 (An Infliximab Biosimilar) Vs Ongoing Reference Infliximab (Remicade (R)) In Patients With Rheumatoid Arthritis: Results Of Phase Iii Transition Study
ARTHRITIS & RHEUMATOLOGY(2016)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要